BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report
financial results for the fourth quarter and full year ended December
31, 2016 after market close on Thursday, February 9, 2017. Following the
earnings release, Innoviva management will host a webcast and conference
call at 5:00 p.m. EST/2:00 PST to discuss the financial results and
provide a corporate update.
To participate in the live call, dial (877) 837-3908 from the U.S., or
(973) 890-8166 for international callers, and enter Conference ID:
56289708. A live webcast of the call will be available at: http://edge.media-server.com/m/p/oopm5ciq
or from the investor relations section of the company website at www.inva.com
and will be archived for 30 days. A telephone replay of the call will be
available through February 16, 2017, by dialing (855) 859-2056 from the
U.S., or (404) 537-3406 for international callers and entering
Conference ID: 56289708.
About Innoviva
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO®
ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest
in future payments made by GSK for earlier-stage programs partnered with
Theravance BioPharma, Inc., including the closed triple combination
therapy for COPD. For more information, please visit Innoviva's website
at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170202005007/en/
Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief
Financial Officer
650-238-9640
investor.relations@inva.com
Source: Innoviva, Inc.
News Provided by Acquire Media